Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3120 in Advanced Solid Tumors
NCT06818643Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Primary completion
- Feb 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 12
01
Overview
A Phase 2 trial of MK-3120 in solid tumor, sponsored by Merck & Co.. Started Mar 2025; status: recruiting.
02
Drugs
MK-3120
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06818643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818643.